Clinical trial
Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine
NCT00197223 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00197223 |
|---|---|
| Title | Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine |
| Official title | A Randomized, Double-blind, Placebo-controlled, Post-marketing Phase III Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine (Fluarix™) Administered Intramuscularly in Adults. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Influenza vaccine |
| Enrollment | 6,213 |
| Start date | Sep 1, 2005 |
| Primary completion | Oct 1, 2005 |
| Completion | May 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Mar 23, 2017 |
| Countries | Czechia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: